Predictors and Outcomes of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphoma.
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment for patients with aggressive relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). One notable complication is immune effector cell-associated neurotoxicity syndrome (ICANS) which can be life-threatening. Treatment includes supportive...